P. Minic (Beograd, Republic of Serbia), H. Heijerman (Utrecht, Netherlands)
This session is built from abstracts published on the ERS Congress platform from 23 August, in an e-poster pdf format with a 3-minute audio narration. Participants and chairs of the session are invited to access all e-posters from 23 August to 4 September prior to the 1-hour live, online discussion scheduled from September 5-7. Please note that during live discussion there will be NO e-poster/abstract presentations, only discussion.
Functional respiratory imaging assessment of the aerosol deposition of inhaled levofloxacin in cystic fibrosis lungs
C. Schwarz (Potsdam, Germany), C. Procaccianti (Parma, Italy), D. Belmans (Kontich, Belgium), B. Mignot (Kontich, Belgium), N. Schwenck (Starnberg, Germany), X. Murgia (Zamudio, Spain), F. Bianco (Parma, Italy), C. Procaccianti (MILAN, Italy)
|   |
In vitro effect of combined hypertonic saline and salbutamol on ciliary beat frequency of human nasal epithelial cells
A. Escher (BernBern, Switzerland), P. Latzin (BernBernBernBern, Switzerland), C. Casaulta (BernBernBern, Switzerland), L. Müller (BernBern, Switzerland)
| |
New algorithm of antibiotic selection reveals the abundance and reduces bacterial load in sputum of adult patients with cystic fibrosis.
G. Tetz (New York, United States of America), C. Kardava (Saint Petersburg, Russian Federation), M. Vecherkovskaya (Saint Petersburg, Russian Federation), T. Gembitskaya (Saint Petersburg, Russian Federation), V. Tetz (Saint Petersburg, Russian Federation)
| |
Assessment of NuvoAir platform use on clinical outcomes in adults with cystic fibrosis: a first Italian experience
V. Carnovale (Naples, Italy), P. Iacotucci (Naples, Italy), P. Medio (Naples, Italy), L. Ferrillo (Naples, Italy), S. Buonaurio (Naples, Italy), M. D'Ippolito (Naples, Italy), A. Celardo (Naples, Italy), S. Coughlin (Stockholm, Sweden), D. Savi (Rome, Italy)
| |
Evaluation of the tolerability of the dornase alfa based on the results of a multicenter scientific program of post-marketing use of the medicine
E. Kondratyeva (Moscow, Russian Federation), V. Shadrina (Perm, Russian Federation), E. Furman (Perm, Russian Federation), A. Voronkova (Moscow, Russian Federation), V. Sherman (Moscow, Russian Federation), E. Zhekaite (Moscow, Russian Federation), O. Simanova (Moscow, Russian Federation), A. Malakhov (Moscow, Russian Federation), M. Mukhina (Moscow, Russian Federation), E. Yakushina (Moscow, Russian Federation), O. Vysokolova (Moscow, Russian Federation), . Ilyenkova (Krasnoyarsk, Russian Federation), S. Trishina (Simferopol, Russian Federation), J. Pinegina (Novosibirsk , Russian Federation), T. Safonova (Omsk, Russian Federation), E. Vasilyeva (Samara, Russian Federation), O. Golubtsova (Cheboksary, Russian Federation)
| |
Nontuberculous mycobacteria (NTM) in Cystic fibrosis (CF) patients over the last decade: real-life data from Verona CF center
F. Lucca (Verona, Italy), G. Cucchetto (Verona, Italy), S. Volpi (Verona, Italy), M. Cipolli (Verona, Italy)
| |
Propofol sedation in lung transplant recipients: the impact of cystic fibrosis.
M. Damin (Padova (PD), Italy), D. Biondini (Padova (PD), Italy), M. Tine (Padova (PD), Italy), E. Cocconcelli (Padova (PD), Italy), M. Rizzo (Padova (PD), Italy), G. Andreotti (Padova (PD), Italy), N. Malacchini (Treviso, Italy), S. Petrarulo (Padova (PD), Italy), F. Lionello (Padova (PD), Italy), M. Cosio (Montreal, Canada), M. Saetta (Padova (PD), Italy)
| |